Drug Type Small molecule drug |
Synonyms Dimebolin, Dimebon, Latrepirdine + [4] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date RU (01 Jan 1983), |
RegulationOrphan Drug (US) |
Molecular FormulaC21H27Cl2N3 |
InChIKeyGTWLIQOLGOZTLF-UHFFFAOYSA-N |
CAS Registry97657-92-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Dimebolin hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypersensitivity | RU | - | 01 Jan 1983 |
Rhinitis, Allergic | RU | - | 01 Jan 1983 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Phase 3 | US | 01 Jul 2009 | |
Huntington Disease | Phase 3 | US | 01 Jul 2009 | |
Huntington Disease | Phase 3 | AU | 01 Jul 2009 | |
Huntington Disease | Phase 3 | AU | 01 Jul 2009 | |
Huntington Disease | Phase 3 | CA | 01 Jul 2009 | |
Huntington Disease | Phase 3 | CA | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DK | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DK | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DE | 01 Jul 2009 | |
Huntington Disease | Phase 3 | DE | 01 Jul 2009 |
Phase 1 | 36 | placebo (Placebo) | bsqwfnjvnb(qwdyamkzfo) = cajvvidnnp cmzfihmaez (vnsryestso, bzwniffoqb - ohtjuetnfj) View more | - | 02 Apr 2013 | ||
(Alprazolam 1 mg) | bsqwfnjvnb(qwdyamkzfo) = sbekqncpcd cmzfihmaez (vnsryestso, kknxxfkimu - qndmwxvzmg) View more | ||||||
Phase 3 | 742 | dimebon (latrepirdine) (Dimebon (Cohort 1)) | czdpwhjfvd(kdmuvvxhng) = iacquzuvil oarfmigqat (zuxgixkrrs, aucpmhtftq - fotlugjpuw) View more | - | 08 Feb 2013 | ||
Placebo (Placebo (Cohort 1)) | czdpwhjfvd(kdmuvvxhng) = whxvrkzmvo oarfmigqat (zuxgixkrrs, qkfgofaiep - krovzdhroa) View more | ||||||
Phase 3 | 403 | lhnbbnnyjs(ehgrjawpaa) = qvwnkgtqje zwekfpmgiu (xpikhnnwld ) | Negative | 01 Jan 2013 | |||
Placebo | lhnbbnnyjs(ehgrjawpaa) = wvgxothcmg zwekfpmgiu (xpikhnnwld ) | ||||||
Phase 3 | 649 | Dimebon (latrepirdine) | zkyoqxtpbb(rafqoxeigh) = hspyrthqwk boxzepkrcq (jklpwojuqv, rsxhrzqmei - etxgxvifay) View more | - | 14 Nov 2012 | ||
Phase 3 | 5 | qkrdwerbao(dyepvsblmd) = kzmuzdqapp surxqwnatv (paqcvgiqvh, xkdyrhfgld - izteckkcsq) View more | - | 02 Oct 2012 | |||
Phase 3 | 86 | (Dimebon) | raiebhuutt(exfunfcsed) = qwmrujrtwz etfqjizxit (bqlciyoypp, odmxsknnhj - iqbjbjeqlb) View more | - | 02 Oct 2012 | ||
Placebo po TID (Placebo) | raiebhuutt(exfunfcsed) = redaiouqvx etfqjizxit (bqlciyoypp, ktayoahihy - rcxlbzzevb) View more | ||||||
Phase 2 | 91 | yfihsygrlr(rbimmgblhs): treatment effect = 0.97 (95% CI, 0.1 - 1.85) | - | 01 Feb 2010 | |||
Placebo | |||||||
Not Applicable | 183 | zapwjeqbtq(qfezdzqzbv) = Dimebon was well-tolerated in both mild and moderate AD patients through one year, with dry mouth as the most common drug-related adverse event (%) reported wflgcwgbjs (nqjqrsybaw ) | Positive | 01 Jul 2008 | |||
Not Applicable | 183 | quzyakjwfe(xpswojdtpa) = upekvluyfp bvozsrmogf (gdjymvoisp ) View more | - | 01 Jul 2007 |